We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00159003
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : August 10, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis.

We are studying these genetic variations in patients with leukemia. The genes we are studying are those which influence detoxification of drugs and toxins.


Condition or disease
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia

Detailed Description:

We have prepared DNA on patients with leukemia (AML, CML and CLL) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1, NAT1/2, GST, hOCT. We plan to study other genes that may be contributory.

Study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of DNA biding proteins which bind at the sites of these polymorphisms.


Study Design

Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel
Actual Study Start Date : January 1, 1998
Primary Completion Date : July 1, 2017
Study Completion Date : July 1, 2017


Groups and Cohorts


Outcome Measures

Biospecimen Retention:   Samples With DNA
DNA only

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients admitted to Hadassah Hospital with AML or CLL.
Criteria

Inclusion Criteria:

  • diagnosis of acute myeloid leukemia or chronic lymphocytic leukemia

Exclusion Criteria:

  • under 18 years of age
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159003


Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel, IL91120
Sponsors and Collaborators
Deborah Rund
Investigators
Principal Investigator: Deborah G Rund, MD Hadassah Medical Organization
More Information

Publications:
Responsible Party: Deborah Rund, Senior Hematologist, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00159003     History of Changes
Other Study ID Numbers: 132910-HMO-CTIL
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: August 10, 2017
Last Verified: August 2017

Keywords provided by Deborah Rund, Hadassah Medical Organization:
drug metabolism and disposition enzymes

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Susceptibility
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Disease Attributes
Pathologic Processes